New agents for thromboprotection: A role for factor XII and XIIa inhibition

Hamostaseologie

Volumn 35, Issue 4, 2015, Pages 338-350

  Labberton, L ^a   Kenne, E ^a   Renné, Thomas ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anticoagulants; Contact system; Factor XII; Polyphosphate

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 8 INHIBITOR; POLYMER; POLYPHOSPHATE; PROCOAGULANT;

BLOOD CLOTTING; ENZYME ACTIVITY; ENZYME CONFORMATION; FIBRIN FORMATION; FIBRINOLYSIS; HEAVY CHAIN; HUMAN; INFLAMMATION; LIGHT CHAIN; MOLECULAR WEIGHT; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTEIN TARGETING; REVIEW; THROMBOCYTE ACTIVATION; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; FIBRINOLYTIC THERAPY; IMMUNOLOGY; PROCEDURES; THROMBOSIS; TRENDS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XII; FACTOR XIIA; HUMANS; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 84964756537     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-14-11-0060     Document Type: Review

References (124)

1. Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
2. Renne T, Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett 2001; 500: 36-40.
3. Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000; 275: 33688-33696.
4. Shariat-Madar Z, Mahdi F, Schmaier AH. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol 2002; 2: 1841-1849.
5. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010; 125: 210-215.
6. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37: 375-381.
7. LaRusch GA, Mahdi F, Shariat-Madar Z et al. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis Blood 2010; 115: 5111-5120.
8. Doolittle RF. Coagulation in vertebrates with a focus on evolution and inflammation. J Innate Immun 2011; 3: 9-16.
9. Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost 2008; 6: 1876-1883.
10. Maas C, Renne T. Regulatory mechanisms of the plasma contact system. Thromb Res 2012; 129 (Suppl 2): S73-S76.
11. Kenne E, Renne T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discovery Today 2014; 19: 1459-1464.
12. Palmer RN, Gralnick HR. Cold-induced contact surface activation of the prothrombin time in whole blood. Blood 1982; 59: 38-42.
13. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50-68.
14. Konings J, Govers-Riemslag JW, Philippou H et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011; 118: 3942-3951.
15. Bjorkqvist J, Nickel KF, Stavrou E, Renne T. In vivo activation and functions of the protease factor XII. Thromb Haemost 2014; 112: 868-875.
16. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003-1010.
17. Coffman LG, Brown JC, Johnson DA et al. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol 2008; 294: L505-L515.
18. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 2002; 99: 896-900.
19. Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol 2005; 289: H2697-H2703.
20. Bjorkqvist J, Jamsa A, Renne T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
21. Lindsay SL, Ramsey S, Aitchison M et al. Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239. J Cell Sci 2007; 120: 3011-3021.
22. Benz PM, Blume C, Moebius J et al. Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alpha II-spectrin-VASP complexes. J Cell Biol 2008; 180: 205-219.
23. Anton KA, Sinclair J, Ohoka A et al. PKA-regulated VASP phosphorylation promotes extrusion of transformed cells from the epithelium. J Cell Sci 2014; 127: 3425-3433.
24. Tiruppathi C, Ahmmed GU, Vogel SM, Malik AB. Ca2+ signaling, TRP channels, and endothelial permeability. Microcirculation 2006; 13: 693-708.
25. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005; 175: 3377-3385.
26. Paegelow I, Trzeczak S, Bockmann S, VietinghoffG. Migratory responses of polymorphonuclear leukocytes to kinin peptides. Pharmacology 2002; 66: 153-161.
27. Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109: 368-374.
28. Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104.
29. Orfeo T, Brummel-Ziedins KE, Gissel M et al. The nature of the stable blood clot procoagulant activities. J Biol Chem 2008; 283: 9776-9786.
30. Bos MH, Camire RM. Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation. J Coagul Disord 2010; 2: 19-27.
31. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2507-2513.
32. RatnoffOD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-613.
33. Kumar R, Carcao M. Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond. Pediatr Clin North Am 2013; 60: 1419-1441.
34. Pauer HU, Renne T, Hemmerlein B et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 2004; 92: 503-508.
35. Renne T, Pozgajova M, Gruner S et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
36. Kleinschnitz C, Stoll G, Bendszus M et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
37. Girolami A, Allemand E, Bertozzi I et al. Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases. Acta Haematol 2010; 123: 210-214.
38. Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18: 349-355.
39. Renne T, Oschatz C, Seifert S, Muller F, Antovic J, Karlman M, et al. Factor XI deficiency in animal models. J Thromb Haemost 2009; 7 (Suppl 1): 79-83.
40. Kravtsov DV, Matafonov A, Tucker EI et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114: 452-458.
41. Mitropoulos KA. High affinity binding of factor XIIa to an electronegative surface controls the rates of factor XII and prekallikrein activation in vitro. Thromb Res 1999; 94: 117-129.
42. Vogler EA, Graper JC, Harper GR et al. Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. J Biomed Mater Res 1995; 29: 1005-1016.
43. Mutch NJ, Waters EK, Morrissey JH. Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation. J Thromb Haemost 2012; 10: 2108-2115.
44. Jordan SW, Chaikof EL. Novel thromboresistant materials. J Vasc Surg 2007; 45 (Suppl A): A104-A115.
45. Frank RD, Mueller U, Lanzmich R, Floege J. Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride. J Mater Sci Mater Med 2013; 24: 2561-25676.
46. Svensson M, Friberger P, Lundstrom O, Stegmayr B. Activation of FXII during haemodialysis. Scand J Clin Lab Invest 1996; 56: 649-652.
47. Cugno M, Nussberger J, Biglioli P et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120: 1776-1782.
48. Bjorkqvist J, Lecher B, Maas C, Renne T. Zinc-dependent contact system activation induces vascular leakage and hypotension in rodents. Biol Chem 2013; 394: 1195-1204.
49. Siebeck M, Cheronis JC, Fink E et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 1994; 77: 2675-2680.
50. Renne T, Schmaier AH, Nickel KF et al. In vivo roles of factor XII. Blood 2012; 120: 4296-4303.
51. Oehmcke S, Morgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009; 1: 225-230.
52. Nickel KF, Renne T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130 (Suppl 1): S78-S83.
53. White-Adams TC, Berny MA, Patel IA et al. Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. J Thromb Haemost 2010; 8: 1295-1301.
54. Van der Meijden PEJ, Munnix ICA, Auger JM et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 114: 881-890.
55. Kuijpers MJE, van der Meijden PEJ, Feijge MAH et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 2014; 34: 1674-1680.
56. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R et al. Platelet-and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-1362.
57. Brunnee T, Reddigari SR, Shibayama Y et al. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 1997; 27: 653-663.
58. Oschatz C, Maas C, Lecher B et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-268.
59. Sala-Cunill A, Bjorkqvist J, Senter R et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 2014; doi: 10.1016/j.jaci.2014.07.057.
60. Bianchini P, Liverani L, Mascellani G, Parma B. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes. Semin Thromb Hemost 1997; 23: 3-10.
61. Blossom DB, Kallen AJ, Patel PR et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359: 2674-2684.
62. Guerrini M, Beccati D, Shriver Z et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-675.
63. Rojkjaer R, Schousboe I. The surface-dependent autoactivation mechanism of factor XII. Eur J Biochem 1997; 243: 160-166.
64. Maas C, Govers-Riemslag JW, Bouma B et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-3218.
65. Kannemeier C, Shibamiya A, Nakazawa F et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-6393.
66. Pavlov V, Zorn M, Kramer R. Probing singlestranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood coagulation cascade. Biochem Biophys Res Commun 2006; 349: 1011-1015.
67. Von Bruhl ML, Stark K, Steinhart A et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
68. Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA 1978; 75: 1998-2002.
69. Johne J, Blume C, Benz PM et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 2006; 387: 173-178.
70. Back J, Sanchez J, Elgue G et al. Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun 2010; 391: 11-17.
71. Johne J, Blume C, Benz PM et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 2006; 387: 173-178.
72. Muller F, Renne T. Platelet polyphosphates: the nexus of primary and secondary hemostasis. Scand J Clin Lab Invest 2011; 71: 82-86.
73. Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279: 44250-44257.
74. Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Int J Hematol 2012; 95: 346-352.
75. Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, Docampo R. Polyphosphate is a novel pro-inflammatory regulator of mast cells and is located in acidocalcisomes. J Biol Chem 2012; 287: 28435-28444.
76. Lorenz B, Leuck J, Kohl D et al. Anti-HIV-1 activity of inorganic polyphosphates. J Acqui Immune Defic Syndr Hum Retroviro 1997; 14: 110-118.
77. Muller F, Mutch NJ, Schenk WA et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
78. Cowling RT, Birnboim HC. Incorporation of [P-32] orthophosphate into inorganic polyphosphates by human granulocytes and other human cell-types. J Biol Chem 1994; 269: 9480-9485.
79. Kulakovskaya TV, Vagabov VM, Kulaev IS. Inorganic polyphosphate in industry, agriculture and medicine: Modern state and outlook. Process Biochem 2012; 47: 1-10.
80. Kornberg A, Rao NN, Ault-Riche D. Inorganic polyphosphate: A molecule of many functions. Ann Rev Biochem 1999; 68: 89-125.
81. Smith SA, Mutch NJ, Baskar D et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
82. Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. J Thromb Haemost 2008; 6: 1750-1756.
83. Montilla M, Hernandez-Ruiz L, Garcia-Cozar FJ et al. Polyphosphate binds to human von Willebrand factor in vivo and modulates its interaction with glycoprotein Ib. J Thromb Haemost 2012; 10: 2315-2323.
84. Gahl WA, Brantly M, Kaiser-Kupfer MI et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 1998; 338: 1258-1264.
85. Hernandez-Ruiz L, Saez-Benito A, Pujol-Moix N et al. Platelet inorganic polyphosphate decreases in patients with delta storage pool disease. J Thromb Haemost 2009; 7: 361-363.
86. Ghosh S, Shukla D, Suman K, Lakshmi BJ et al. Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood 2013; 122: 1478-1486.
87. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970.
88. Choi SH, Smith SA, Morrissey JH. Polyphosphate accelerates factor V activation by factor XIa. Thromb Haemost 2014; 113: http://dx.doi.org/10.1160/TH14-06-0515
89. Smith SA, Choi SH, Davis-Harrison R et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-4359.
90. Mutch NJ, Engel R, Uitte de Willige S et al. Polyphosphate modifies the fibrin network and downregulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-3988.
91. Nickel KF, Spronk HM, Mutch NJ, Renne T. Timedependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122: 3847-3849.
92. Morrissey JH, Smith SA. Comment on Faxalv et al. "Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII". Blood 2013; 122: http://dx.doi.org/10.1182/blood-2013-05-499384.
93. Travers RJ, Shenoi RA, Kalathottukaren MT et al. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124: 3183-3190.
94. Matafonov A, Leung PY, Gailani AE et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; 123: 1739-1746.
95. Revenko AS, Gao DC, Crosby JR et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
96. Yau JW, Liao P, Fredenburgh JC et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 2014; 123: 2102-2107.
97. Yau JW, Stafford AR, Liao P et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomaterial 2012; 8: 4092-4100.
98. Campos IT, Tanaka-Azevedo AM, Tanaka AS. Identification and characterization of a novel factor XIIa inhibitor in the hematophagous insect, Triatoma infestans (Hemiptera: Reduviidae). FEBS Lett 2004; 577: 512-516.
99. Hagedorn I, Schmidbauer S, Pleines I et al. Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-1517.
100. Chen JW, Figueiredo JL, Wojtkiewicz GR et al. Selective factor XIIa inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation pathway. JACC Cardiovasc Imaging 2012; 5: 1127-1138.
101. Xu Y, Cai TQ, Castriota G et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014; 111: 694-704.
102. Larsson M, Rayzman V, Nolte MW et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222ra17.
103. Bhandari R, Juluri KR, Resnick AC, Snyder SH. Gene deletion of inositol hexakisphosphate kinase 1 reveals inositol pyrophosphate regulation of insulin secretion, growth, and spermiogenesis. Proc Natl Acad Sci USA 2008; 105: 2349-2353.
104. Alvarenga PH, Xu XQ, Oliveira F et al. Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate. Arterioscler Thromb Vasc Biol 2013; 33: 2759-2770.
105. Jain S, Pitoc GA, Holl EK et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci USA 2012; 109: 12938-12943.
106. Smith SA, Choi SH, Collins JNR et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120: 5103-5110.
107. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let's meet the challenge. Int J Pharm 2010; 394: 122-142.
108. Jones CF, Campbell RA, Brooks AE et al. Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS nano 2012; 6: 9900-9910.
109. Saito H, Ishihara T, Suzuki H, Watanabe T. Production and characterization of a murine monoclonal-antibody against a hevay-chain of Hageman factor (factor XII). Blood 1985; 65: 1263-1268.
110. Small EJ, Katzmann JA, Tracy RP et al. A monoclonal-antibody that inhibits activation of human Hageman-factor (factor XII). Blood 1985; 65: 202-210.
111. Pixley RA, Stumpo LG, Birkmeyer K et al. A monoclonal-antibody recognizing an icosapeptide sequence in the heavy-chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 1987; 262: 10140-10145.
112. Pixley RA, De La Cadena R, Page JD et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-68.
113. Jansen PM, Pixley RA, Brouwer M et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87: 2337-2344.
114. Isawa H, Yuda M, Orito Y, Chinzei Y. A mosquito salivary protein inhibits activation of the plasma contact system by binding to factor XII and high molecular weight kininogen. J Biol Chem 2002; 277: 27651-27658.
115. Ishimaru Y, Gomez EA, Zhang FF et al. Dimiconin, a novel coagulation inhibitor from the kissing bug, Triatoma dimidiata, a vector of Chagas disease. J Exp Biol 2012; 215: 3597-3602.
116. Baeriswyl V, Calzavarini S, Gerschheimer C et al. Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy. J Med Chem 2013; 56: 3742-3746.
117. WoodruffRS, Xu Y, Layzer J et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost 2013; 11: 1364-1373.
118. Esnouf MP, Burgess AI, Dodds AW et al. A monoclonal antibody raised against human betafactor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C(1)over-bar esterase inhibitor. Thromb Haemost 2000; 83: 874-881.
119. Hojima Y, Pierce JV, Pisano JJ. Hageman-factor fragment inhibitor in corn seeds-purification and characterization. Thromb Res 1980; 20: 149-162.
120. Ulmer JS, Lindquist RN, Dennis MS, Lazarus RA. Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein. FEBS Lett 1995; 365: 159-163.
121. Caliezi C, Wuillemin WA, Zeerleder S et al. C1-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52: 91-112.
122. Rajapakse N, Jung WK, Mendis E et al. A novel anticoagulant purified from fish protein hydrolysate inhibits factor XIIa and platelet aggregation. Life Sci 2005; 76: 2607-2619.
123. Robert S, Bertolla C, Masereel B et al. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem 2008; 51: 3077-3080.
124. Decrem Y, Rath G, Blasioli V et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009; 206: 2381-2395.